The stock market has been on a roll lately, but there's one thing that could put a stop to its bull run: inflation. With the Consumer Price Index rising due to higher gasoline prices, Pimco bond expert Bill Gross says that inflation is coming and that it could hurt economic growth. Consumer sentiment also fell somewhat in February. But overall, the market didn't react strongly, with the Dow Jones Industrials (INDEX: ^DJI) rising just nine points to 13,262 at around 10:50 a.m. EDT. The S&P 500 rose two points to 1,404.

Among Dow stocks, Johnson & Johnson (NYSE: JNJ) was fractionally lower after its Incivo hepatitis C drug got a favorable draft recommendation from U.K. health-care pricing regulators. With huge interest in hepatitis C treatments in recent months, it's important to remember that companies not only have to produce effective treatments, but they also have to demonstrate that they're cost-effective for national health programs.

Intel (Nasdaq: INTC) rose 0.4% after it reportedly bought a stake in Sweden's Tobii Technologies for $20.8 million. Tobii makes technology that allows PCs to track eye movements, letting you control your computer simply by looking at different parts of the screen. If the technology could be adapted for mobile devices, it could represent a big competitive move for Intel.

Finally, Merck (NYSE: MRK) was up 0.5%. An FDA staff report about its ridaforolimus drug for sarcoma, which it developed with Ariad Pharmaceuticals (Nasdaq: ARIA), raised concerns that the drug didn't extend patients' survival or halt the progression of the disease. But the drug will go before an FDA advisory panel next week, which is typically the last step before the agency makes a final decision on approval. Ariad dropped almost 3% on the news.

Keep your perspective
Even if the bull market ends, the best stocks will thrive in the long run. Learn about the one stock the Fool's chief investment officer picked to crush the market in this free report: "The Motley Fool's Top Stock for 2012." Instant access is just a click away.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.